Oncology trial operations

Non-small cell lung cancer clinical trial operations

For a biomarker-selected non-small cell lung cancer (NSCLC) cohort, a patient may arrive with a local report while the study still needs a specified assay, specimen, or central confirmation. Build the screening plan around the result the protocol accepts.

Where study execution gets difficult

NSCLC studies can differ by histology, stage, molecular profile, and previous treatment. When a protocol requires a particular tissue specimen or assay, tissue availability, adequacy, and result turnaround shape the screening workload. In perioperative or post-chemoradiation cohorts, procedure and treatment completion dates can add a separate scheduling dependency.

What the study team can do

Separate the local finding, specimen status, and qualifying result in the tracker. Have the CRA check the tissue and report records against the protocol. Have the CTM agree on the lab contact, turnaround expectations, and timing for escalation to the designated eligibility reviewer.

When this handoff needs a sponsor decision, use an executive briefing to clarify who owns it and what evidence will guide the decision.

Request an executive briefing →

What each role can own

Oncology CRA

Track the site’s specimen and test records and reconcile prior targeted-therapy dates where the cohort requires them.

CTM or Clinical Study Manager

Agree on tissue routing, turnaround expectations, and the escalation point for an inadequate specimen or pending result.

Cross-site monitoring review

Separate tissue inadequacy, lab turnaround, and handoff delays across sites, including recurring misses after surgery or chemoradiation.

A Lead CRA can coordinate recurring findings. For scoped SIGNAL Managed Monitoring, a named review lead brings patterns and open actions to the sponsor’s decision owners.

What to put in the staffing brief

  1. Specify the qualifying biomarker, accepted test and specimen, and how the protocol handles incomplete or discordant reports.
  2. Confirm who checks tissue adequacy and who follows the handoff from pathology through result review.
  3. Define the CRA’s site follow-up and the CTM’s decision route when a result is pending near the planned start.

Related experience and references